Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CET

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
03:50p NOVARTIS : receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positi..
02/24 NOVARTIS : U.S. Patents Awarded to Inventors in Virginia (Feb. 24)
02/24 NOVARTIS AG : Blog Coverage Novartis Gains Priority Review from the FDA for its ..
02/24 NOVARTIS : receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-posi..
02/24 NOVARTIS : Patent Issued for Methods of Nuclease-Based Genetic Engineering (USPT..
02/23 NOVARTIS : drug Zykadia receives FDA Priority Review for first-line use in patie..
02/22 MANUFACTURING DELAY OF GENERIC DRUG : PFE) A Relief For Teva Pharmaceutical Ind..
02/16 JOHNSON & JOHNSON : Nancy-Ann DeParle and Dr. Scott Gottlieb Join Executives fro..
02/15 NOVARTIS : Sources Sought Notice - Alcon Wavecards
02/14 IMMUNICUM : Appoints Karin Hoogendoorn as Head of CMC
More news
Sector news : Pharmaceuticals - NEC
09:38pDJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
06:13p FTSE ends higher on some positive earnings, insurers slip
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:03a RESVERLOGIX : The Science Is Getting 'BETter' For RVX208
02/24 European advisory committee positive actions
02/23 FDA to accelerate review of Novartis' marketing application for Zykadia in fi..
02/22 Momenta Delay Means Race For Copaxone Generic Is On
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
Advertisement
Financials ($)
Sales 2017 48 441 M
EBIT 2017 11 334 M
Net income 2017 7 521 M
Debt 2017 16 963 M
Yield 2017 3,69%
P/E ratio 2017 23,33
P/E ratio 2018 20,48
EV / Sales 2017 4,53x
EV / Sales 2018 4,29x
Capitalization 202 648 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 80,4 $
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG4.72%202 648
JOHNSON & JOHNSON6.53%333 891
ROCHE HOLDING LTD.5.42%210 192
PFIZER INC.5.48%207 902
MERCK & CO., INC.12.38%182 412
SANOFI4.79%109 848
More Results